New PET tracer could reveal which cancers will respond to immunotherapy
NCT ID NCT05888532
First seen Mar 30, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study tests a new radioactive tracer called 64Cu-GRIP B that lights up immune activity in PET scans. It aims to see if the tracer is safe and can help detect which advanced cancers (like prostate, kidney, or bladder) are more likely to respond to immunotherapy. About 91 adults with advanced solid tumors will participate. The goal is to develop a better way to monitor treatment response without invasive biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.